Introduction: Oxyntomodulin (OXM) is a gut hormone released from intestinal L cell. Synthetic OXM and its analog reduce food intake and body weight in both rodents and human beings by being administered intravenously. However, people find intravenous administration difficult because of its side effects and inconvenience. The aim of this study is to develop a novel oral delivery system for OXM and its analog using genetically engineered Bifidobacterium as the carrier. Methods: An OXM gene expression vector pBBADs-OXM for the Bifidobacterium genus was constructed. Human OXM sequence was fused with extracellular exo-xylanase (XynF) signal peptide (Xs) from Bifidobacterium longum under the control of the pBAD promoter. B. longum NCC2705 was transformed with the recombinant plasmid pBBADs-OXM by electroporation, and the transformed B. longum was selected using MRS plates containing 60 mg ml À1 ampicillin. The OXM expression in vitro was identified by western blot and enzyme-linked immunosorbent assay (ELISA) assay after L-arabinose induction. Overweight BALB/c mice were treated with B. longum transformed with OXM after 0.2% L-arabinose induction every day for 4 weeks to investigate the effects of OXM-transformed B. longum on food intake and body weight by oral administration. The B. longum transformed with the green fluorescent protein (GFP) gene was used as negative control; orlistat, a gastrointestinal lipase inhibitor, was used as positive control; Normal saline (NS, 0.9% saline) was used as blank control. The food intakes of each group were measured every day, and body weights were measured once a week. Normal BALB/c (2 months old) mice were treated with OXM-transformed B. longum after induction by intragastric administration every day for 6 days to reveal the mechanism of transformed B. longum, with OXM exerting its biological function by oral administration. Plasma OXM, plasma ghrelin and the OXM of intestinal contents were detected by the ELISA method. Plasma glucose and triglyceride levels were analyzed using the Automatic Biochemistry Analyzer. Results: Transformed B. longum with OXM was selected and identified without biological and morphological alteration. An approximately 4-5 kDa OXM peptide was detected in both the supernatant and the cell pellet of transformed B. longum after L-arabinose induction in vitro. The food intake, body weight and blood triglyceride level of overweight mice treated with OXMtransformed B. longum were all significantly reduced compared with that of the GFP negative control group and NS control group (Po0.01). Interestingly, the plasma triglyceride level of the GFP group was significantly decreased compared with that of the NS control group (Po0.01). The OXM level in the intestinal contents of the OXM group was significantly increased compared with that of the GFP negative control group and the NS group (Po0.05). The plasma ghrelin level of the OXM group was significantly decreased compared with that of the GFP and NS groups (Po0.01). Unexpectedly, the ghrelin level of the GFP group was significantly increased compared with that of the NS control group (Po0.01). Conclusion: A novel oral delivery system of Bifidobacterium for human OXM has been successfully established. The expression of recombinant OXM can be detected in the supernatant and cell pellet of transformed B. longum. OXM-transformed B. longum reduces food intake, body weight and plasma lipid level in overweight mice by oral administration.
Introduction
Oxyntomodulin (OXM) is a 37-amino acid peptide released from intestinal L cell and the central nervous system. 1 OXM originates from posttranslational processing of proglucagon and other proglucagon-derived peptide members, such as glucagon-like peptide-1 (GLP-1), GLP-2 and glicentin. 2, 3 It was named after its inhibitory action on the oxyntic glands of the stomach. 4 OXM potently inhibits gastric acid secretion and pancreatic enzyme secretion. 5 It is considered to be an effective regulator of appetite and body weight. The release of OXM is in response to nutrient intake and in proportion to the calories consumed. 6 OXM levels are markedly elevated in tropic malabsorption and after jejunoileal bypass surgery for morbid obesity. [7] [8] [9] Previous studies have shown that both intracerebroventricular and intraperitoneal administration of OXM reduce food intake and body weight gain in rodents. 10, 11 Furthermore, intravenous infusion or subcutaneous injection of OXM has shown a double effect of suppressing appetite and increasing energy expenditure in overweight and obese humans without altering their enjoyment of food. 12, 13 The weight loss rate of volunteers treated with OXM is much higher than that of any currently licensed antiobesity drugs. 14 These studies have indicated that OXM is a potential therapeutic drug for obesity. However, injection is still the main approach for peptide drug delivery till now. It is not easy for obese or overweight people to receive intravenous administration for a long time.
A new delivery approach, such as oral administration, should be developed for OXM, GLP-1 and other peptide drugs. The genera Bifidobacterium are the dominant probiotic bacteria inhabiting the distal jejunum, ileum and large intestine of humans and other warm-blooded animals. Bifidobacterium spp has many beneficial effects on human health, including preventing infection, immunomodulation, reducing serum cholesterol, promoting lactose digestion and protecting against colon cancer. [15] [16] [17] [18] Recently, genetically engineered Bifidobacterium has been used as an exogenous gene delivery carrier of cytosine deaminase and interleukin-10 for cancer gene therapy and bowel disease treatment. [19] [20] [21] Moreover, Bifidobacterium longum was used as the host for recombinant pediocin PA-1 expression and secretion under the guide of a-amylase signal peptide. 22 It suggests that Bifidobacterium spp may be the most suitable host (carriers) for human gut hormone gene expression and secretion in the intestinal tract for obesity and diabetes therapy. In this study, we describe a novel oral delivery system of Bifidobacterium for OXM by constructing an Escherichia coliBifidobacterium shuttle vector. The expression characters of human OXM in Bifidobacteria in vitro were analyzed, and the therapeutic effects of OXM-transformed B. longum after oral administration on overweight mice were evaluated and confirmed.
Materials and methods
Animals, bacterial strains, enzymes, reagents and plasmids Female BALB/c mice (3 or 8 weeks old) were purchased from the Laboratory Animal Center (Southern Medical University, Guangzhou, PR China). Mice were maintained in a temperature-controlled room (21- Gene expression induction in vitro Transformed bacteria were cultured in MRS broth with 60 mg ml À1 ampicillin. L-arabinose was added to induce target gene expression after the bacterial suspension optical density (OD) 695 nm reached B0.6. Culture supernatants and bacterium pellets were collected at 6, 12, 24 and 48 h after 0.2% L-arabinose induction and stored at À70 1C.
Preparation of overweight mice
A total of 60 female BALB/c mice were fed a high-fat diet (40% fat) without limit for food and water to prepare overweight mice. A group of mice (n ¼ 8) fed a standard rodent diet was used as chow-fed controls. Food intake and body weight were measured once a week. The overweight mouse was confirmed when its body weight was 20% heavier than that of the chowfed mouse after 3-4 weeks of being fed a high-fat diet.
Animal experiment protocol
To investigate the effects of OXM-transformed B. longum on food intake and body weight, 32 overweight mice were chosen and divided randomly into four groups. The OXM group (n ¼ 8) was treated with 0.9 ml (6 Â 10 8 per ml) OXMtransformed B. longum after 12 h of 0.2% L-arabinose induction by intragastric administration every day; the GFP group (n ¼ 8) was treated with 0.9 ml (6 Â 10 8 per ml) GFPtransformed B. longum and was used as the negative control; the orlistat group (n ¼ 8) was treated with 1.0 g kg À1 (weight)
orlistat, a gastrointestinal lipase inhibitor, dissolved in NS (0.9% saline) and was used as the positive control; the NS group (n ¼ 8) was treated with 0.9 ml NS only and was considered as the blank control. The food intakes of each Bifidobacterium as OXM oral delivery carrier for obesity therapy RT Long et al group were measured every day, and body weights were measured once a week. To investigate the effects of OXMtransformed B. longum on OXM and ghrelin levels in plasma, 36 normal BALB/c mice (8 weeks old) were randomly divided into three groups. The OXM group (n ¼ 12) was treated with 0.9 ml (6 Â 10 8 per ml) induced OXM-transformed B. longum by intragastric administration every day; the GFP group (n ¼ 12) was treated with 0.9 ml (6 Â 10 8 per ml) induced GFP-transformed B. longum and was considered as the negative control; the NS group (n ¼ 12) was treated with 0.9 ml NS and was considered as the blank control. The animals were killed 6 days later. The intestinal contents of ileocecum and peripheral blood were collected. All animal experiments abided by the Administration Regulations of Experimental Animal of the South Medical University, PR China. Plasma levels of glucose and triglyceride were determined using a Hitachi7600-010 Automatic Biochemical Analyzer (Hitachi Ltd, Tokyo, Japan). The tissue slides of blood vessels, liver, kidney and colon were stained with hemotoxylin and eosin, and then examined using a microscope.
ELISA assay
The culture supernatant and serum samples were directly added to the microwell plate for ELISA detection. Whole-cell protein extract of pellets was prepared as follows: each pellet (1.5 ml bacteria culture) was resuspended in 60 ml TES lysis buffer (10 mmol l À1 Tris-HCI, 1.0 mmol l À1 EDTA, 150 mmol l phosphate buffer and were centrifuged 10 000 Â g at 4 1C. The test procedures were carried out according to the instruction manual provided in the kits. Serum sample (20 ml), supernatant sample or 10 ml pellet lysate was added to each well.
Western blot
Before electrophoresis, proteins in the supernatant sample were precipitated with trichloroacetic acid and washed twice with acetone. Whole-cell protein extract of pellets was prepared using the ELISA method with an additional 20 ml 4 Â SDS loading buffer. Sample proteins were separated in 15% (w/v) SDS-PAGE and transferred to a polyvinylidene fluoride membrane (Pall Ltd, East Hills, NY, USA). The OXM expressions in supernatants and pellets were detected using the western blot method with rabbit anti-OXM IgG and monitored with enhanced chemiluminescence. Bifidobacterium as OXM oral delivery carrier for obesity therapy RT Long et al bacteria or bacteria transformed with pBBADs-GFP. The species of B. longum was identified by amplifying 16s RNA recombinant DNA by PCR. A band of 800-bp fragment was obtained from transformed bacteria, and negative result was obtained from E. coli (Figure 2b ).
Statistical analysis

Detection of OXM expression in B. longum in vitro
The expression of recombinant OXM from OXM-transformed B. longum in vitro was detected by ELISA and western blot. OXM expression could be detected in supernatants and pellets of OXM-transformed bacteria. The concentrations of OXM in supernatants were extremely higher than that of cell pellets (three repeat expressions) (Figure 3b ). The levels of recombinant OXM in both supernatants and pellets increased with induction time. The level of supernatant reached a maximum at 12 h, whereas the level of pellet reached a maximum at 24 h. The result of western blot showed that B5-kDa protein bands were observed on the lanes of both supernatants and pellet lysates. It is concordant with the 4.7-kDa theoretical molecular weight of mature OXM. No reaction band presented on the lane of preinduced transformed bacteria (Figure 3a) .
Effects on food intake and body weight
The daily intake of the OXM group (total intake of one group, n ¼ 8) began to decrease after 1-week oral administration of OXM-transformed B. longum. The daily intake in the fourth week decreased significantly compared with that of the negative control GFP group and that of the NS control group (7.79 ± 0.44 g vs GFP group 11.31 ± 0.39 g and NS group 11.23±0.70 g, Po0.01), whereas it was almost similar (6.93 ± 0.29 g) in the chow-fed group. There was no difference between the daily intake of the OXM group and that of the orlistat group (P40.05) (Figure 4 ). The body weight of the OXM group also began decreasing after 1-week oral administration of OXM-transformed B. longum. It decreased significantly compared with that of the GFP and NS groups (33.19±2 .41 g vs GFP group 38.98±1.28 g and NS group 42.00 ± 3.09 g, Po0.01). No difference appeared between the body weight of the OXM group and that of the orlistat group (P40.05); Interestingly, the body weight of the GFP group decreased slightly compared with that of the NS group (Po0.05) ( Figure 5 ).
Effects on plasma lipid
The effect of OXM-transformed B. longum on plasma lipid by oral administration was also investigated. Blood triglyceride levels of the OXM and orlistat groups decreased significantly compared with that of the NS group (1.66 ± 0.34 and 1.41 ± 0.64 vs 5.39 ± 1.87 mmol l
À1
, Po0.001). They were even lower than that (1.96±0.67 mmol l
) of the chow-fed group, although no statistical difference appeared. Interestingly, the blood triglyceride level of the GFP group also decreased significantly compared with that of the NS group (2.03±0.44 vs 5.39±1.87 mmol l À1 , Po0.001) (Figure 6 ). No differences in plasma glucose levels were found between the OXM and the GFP or NS groups. Pathological changes in Bifidobacterium as OXM oral delivery carrier for obesity therapy RT Long et al blood vessel, liver and kidney tissues were not observed in any group by the hemotoxylin and eosin staining method (data not presented).
OXM level in intestinal contents
After 6 days oral administration of OXM-transformed B. longum, the OXM level of the intestinal contents of the OXM group was significantly increased compared with that of the GFP negative control and NS control groups (50.24 ± 15.29 pg ml À1 vs GFP group 36.31 ± 12.29 pg ml
À1
and NS group 33.21±8.01 pg ml À1 , Po0.05) (Figure 7) . No difference was observed between the GFP and NS groups. However, a high deviation of OXM levels appeared in all groups. It might be because of the high heterogeneity of liquid water content in intestinal contents.
Effects on plasma OXM and ghrelin
There were no differences in plasma OXM concentration between the OXM group and the GFP or NS groups (36.18 ± 3.87 pg ml À1 vs GFP group 37.04 ± 4.87 pg ml À1 and NS group 38.23 ± 4.13 pg ml
À1
, P40.05) (Figure 8) . The plasma ghrelin level of the OXM group was significantly decreased compared with that of the GFP and NS groups (12.28 ± 0.58 pg ml À1 vs GFP group 32.15 ± 1.57 pg ml À1 and NS group 23.68±3.63 pg ml
, Po0.01). Unexpectedly, the plasma ghrelin level of the GFP group was significantly higher than that of the NS group (Po0.001) (Figure 9 ).
Discussion
Previous studies including clinical trials have shown that OXM significantly reduces food intake and body weight in rats and human beings by systemic administration (intravenous, intraperitoneal or subcutaneous injection) or intracerebroventricular injection. [10] [11] [12] [13] However, almost all peptide drugs including OXM are still administrated intravenously. Not only is intravenous administration inconvenient but it also causes many side effects, such as infection, allergy and angeitis. Bifidobacterium as OXM oral delivery carrier for obesity therapy RT Long et al
In this study, we described a novel oral delivery system for OXM by using genetically engineered Bifidobacterium as the carrier. The results show that OXM-transformed B. longum reduces food intake, body weight and decreases blood lipid in overweight mice by oral administration. The benefits of OXM-transformed B. longum on reduction of food intake, body weight and blood lipid are similar to that of orlistat, a new gastrointestinal lipase inhibitor drug for obesity therapy. Furthermore, B. longum itself has many other beneficial functions for health without side effects (such as steatorrhea, nutrition imbalance, allergy, angeitis and so on), which are always caused by orlistat and intravenous administration.
The oral administration of GFP-transformed Bifidobacteria significantly decreases blood triglyceride levels in overweight mice than NS (Po0.001). It is concordant with other reports that wild Bifidobacteria reduce plasma cholesterol and lipid. [25] [26] [27] The blood triglyceride level of the OXM group is slightly lower than that of the GFP group. It suggests that OXM may promote lipid reduction of wild Bifidobacterium, although no statistical difference emerged.
To reveal the mechanism of action of OXM-transformed B. longum by oral administration on food intake and body weight, we investigated the OXM and ghrelin levels in blood circulation in the experimental mice. Previous studies have shown that intact small protein and peptide can be absorbed by intestinal mucosa epithelium and be detected in the portal vein and peripheral blood. 28, 29 We hypothesize that being absorbed into circulation is one of the probable pathways by which recombinant OXM of transformed B. longum exerts its biological functions. Although the OXM level of the intestinal contents of OXM-transformed B. longum-treated mice was higher than that of GFPtransformed B. longum-treated mice, no differences in plasma OXM levels were found between the OXM and GFP control groups. The reason may be the rapid degradation of OXM and insufficient numbers of experimental animals. We still believe that a small amount of OXM from B. longum may be absorbed by gastrointestinal mucosa epithelium and may enter into blood circulation to exert its effects on appetite and energy expenditure. Acting directly on gastrointestinal epithelial cells may be the main probable pathway of recombinant OXM exerting its biological functions by oral administration. OXM can bind to both glucagon and GLP-1 receptor (GLP-1R). 30, 31 GLP-1R is necessary for the anorectic effects of OXM, as well as for the anorectic effects of other GLP-1R agonists, namely, GLP-1 and exendin-4 (Ex-4). GLP-1R is widely expressed, being found in the gastrointestinal tract, pancreas, lung, heart and centrally in the hypothalamus. 32, 33 Oral administration of OXM-transformed Bifidobacteria may directly act on GLP-1R or on an unidentified receptor in the gastrointestinal epithelium, and may then increase energy expenditure and decrease energy intake. It has been reported that GLP-1, CCK, PYY and other gut hormones can inhibit the release of ghrelin through vagus nerve stimulation. [34] [35] [36] Recombinant OXM in the intestinal tract may also stimulate the vagus nerve, followed by inhibition of ghrelin release by acting on its receptors. Further experiments are required to elucidate the mechanisms by which OXM exerts its effects on food intake and energy expenditure by oral administration.
Ghrelin is a powerful signal molecule of appetite. It rises preprandially in the plasma and is considered to be a trigger for meal initiation. 37, 38 The inhibitory effects of OXM on plasma ghrelin level by intravenous administration have already been reported. 39, 40 In this study, oral administration of OXM-transformed B. longum decreases the ghrelin plasma level significantly. The result presented is concordant with previous data. Our results also confirm that oral administration of OXM-transformed B. longum does have definite biological effects on appetite. The mechanism by which GFP-transformed B. longum increases ghrelin plasma level is unclear. We hypothesize that the beneficial promotion of Bifidobacteria to gastrointestinal digestive function may be responsible for the increasing plasma ghrelin level.
The recombinant OXM levels in the supernatants of transformed B. longum culture at different times after induction in vitro are extremely higher than that inside cells (pellets). It demonstrates that OXM in transformed B. longum is expressed as a mature secretory peptide, and the XynF signal peptide coming from B. longum is suitable to guide exogenous protein secretion in engineering Bifidobacterium spp. More studies are required to elucidate the expression and absorption characters of recombinant OXM from engineering B. longum in intestinal tract, and to ensure the safety of transformed B. longum to gastrointestinal microecology in mammals.
In conclusion, an expression vector for Bifidobacterium spp has been established as a novel oral delivery carrier for OXM and other peptides. The OXM expression in transformed B. longum can be detected in supernatant and inside cells after L-arabinose induction. OXM-transformed B. longum reduces food intake, body weight and blood lipid levels in overweight mice by oral administration.
